Navigation Links
DOR BioPharma Announces Publication Describing Results of Its,Multivalent Botulinum Toxin Vaccine BT-VACC

s based on non-toxic subunits are being developed, including BT-VACC™.

About DOR BioPharma, Inc.

DOR BioPharma, Inc. is a biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal ("GI") diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec® (oral beclomethasone dipropionate), is a potent, locally acting corticosteroid being developed for the treatment of GI graft-versus-host disease ("GVHD"), a common and potentially life-threatening complication of bone marrow transplantation. DOR has filed an NDA with the FDA for the treatment of GI GVHD, and has received a PDUFA date of July 21, 2007. An MAA with the EMEA for orBec® has also been filed and validated. orBec® may also have application in treating other gastrointestinal disorders characterized by severe inflammation. DOR has also recently initiated a clinical development program with its Lipid Polymer Micelle ("LPMTM") oral drug delivery technology for the oral delivery of leuprolide for the treatment of prostate cancer and endometriosis.

Through its Biodefense Division, DOR is developing biomedical countermeasures pursuant to the recently enacted Project BioShield Act of 2004. DOR's biodefense products in development are recombinant subunit vaccines designed to protect against the lethal effects of exposure to ricin toxin and botulinum toxin. DOR's ricin toxin vaccine, RiVax™, has been shown to be safely tolerated and immunogenic in a Phase 1 clinical trial in normal volunteers.

For further information regarding DOR BioPharma, please visit the Company's website located at www.dorbiopharma.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, that reflect DOR BioPharma, Inc.'s current expectations about its future r
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
2. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
5. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
6. AVI BioPharma Reports Positive Pre-Clinical Influenza Data
7. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
8. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
9. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:10/7/2008).... 7 / Burcon NutraScience,C...ratein(R) and,Supertein(TM) canola protein isolate...r intended use in a variety of food and beverage,a...GRAS through an,independent evaluation by a panel ... toxicology, nutritional sciences, food allergies ...
(Date:10/7/2008)...ct. 7 /- CEL-SCI Corporatio...d into a Material Transfer,Agreement (MTA) with th...IHCC) and the laboratory of Dr. Francesco M. Marin...changes to the tumor microenvironment,caused by CE...e Chief of,the Infectious Disease and Immunogentic...
(Date:10/7/2008)...Colo., Oct. 7 /- A study published in... stem cell self-renewal,reported that InVitria,s ...,human serum albumin) was an effective replacement... article entitled, "The ground state of embryonic ...s used Cellastim as a recombinant,albumin in place...
(Date:10/7/2008)...s., Oct. 7 /- Taligen Therapeutics In... the Company,s pipeline,candidates were presented ...asel, Switzerland. The data highlighted the candid...ent-mediated diseases., "These highlighted presen...nted at the conference, reveal the deep expertise ...
Breaking Medicine Technology:Burcon announces GRAS status for Puratein(R) & Supertein(TM) 2Burcon announces GRAS status for Puratein(R) & Supertein(TM) 3CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 2CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 3In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 2In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 3In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 4World Bank Group Report on Malaria in Africa Highlights Progress Towards Goal of Significantly Reducing Malaria Deaths 3502 1World Bank Group Report on Malaria in Africa Highlights Progress Towards Goal of Significantly Reducing Malaria Deaths 3502 2World Bank Group Report on Malaria in Africa Highlights Progress Towards Goal of Significantly Reducing Malaria Deaths 3502 3National Award Recognizes Delmarva Foundation and CareFirst BlueCross BlueShield Quality Improvement Efforts 3500 1National Award Recognizes Delmarva Foundation and CareFirst BlueCross BlueShield Quality Improvement Efforts 3500 2Hospital Coalition Says Governors No Fault Bill Signing Provides a Great Protection for Florida Consumers 3498 1Hospital Coalition Says Governors No Fault Bill Signing Provides a Great Protection for Florida Consumers 3498 2Study Author Urges Peers to Stop Using Pain Pumps in the Shoulder Joint as Seasonal Surge in Use Approaches 3496 1Study Author Urges Peers to Stop Using Pain Pumps in the Shoulder Joint as Seasonal Surge in Use Approaches 3496 2Study Author Urges Peers to Stop Using Pain Pumps in the Shoulder Joint as Seasonal Surge in Use Approaches 3496 3
...y 5 /PRNewswire-FirstCall/ -- Nuvelo,Inc. (Nasdaq...(Anticoagulation with rNAPc2 To Help Eliminate MAC...matode anticoagulant protein c2,(rNAPc2) in patien...l data evaluating rNAPc2 in mouse models of colore...echanism of NU172, a,short-acting, direct thrombin...
...USINESS WIRE)--Jul 5, 2007 - Australian,biotechnol...mpletion of apricitabine,s controlled, double blin...nt of its Phase IIb trial.,Patients have now progr...eks 24 to 48) and will continue to receive 800mg,a...atment regime.,The Company expects to release resu...
Other Medicine Technology:Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst,Congress of the International Society on Thrombosis and Haemostasis 2Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst,Congress of the International Society on Thrombosis and Haemostasis 3Avexa's Apricitabine Clinical Trial Update 2
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
...s at the University of Siena, researchers found th... alleviating pain felt by children during medical ...n the study, Carlo Belliene and his team from Le S...ldren, aged between 7 and 12, into three groups at...
...boils and pimples severe enough to send people to ... deadly// bacterium that cannot be treated with co...in resistant staphylococcus aureus (MRSA) is found...oft tissue infections in 11 emergency rooms acros...
...ancer” initiative at Roswell Park Cancer Institute...omen’s health //after they are diagnosed with brea...d prevention of cancer recurrence. The comprehens...Chen Hong, PhD, and Christine Ambrosone, PhD, Depa...
...ides affecting how people relate to others, accord...aborative Program of Excellence in Autism compared... 15, with 56 who did not have the condition. It w...sm were found to have more problems with complex t...
Other Medicine News:Health News:Deadly superbug on the rise 2Health News:Study Focuses on Women's Health After Breast Cancer 2Health News:Multiple Parts of the Brain Affected by Autism 2
...eica ASP200 is an advanced smart processor for par...ne histopathology applications. Proven and enhance... smart operating software are the hallmark of the ...ed and the software includes a variety of SMART fe...
The electronic, motorized rotary microtomes are designed for all applications of paraffin, semi-thin (HM 360), and hard specimens in clinical, research, and industrial labs. These instruments display
...eica RM2255 rotary microtome, designed for fully m...bedded specimens, offers a broad application spect...ory. This microtome meets the requirements of user...c microtome for their laboratory. The entire acces...
State-of-the-Art modular embedding station providing performance and ease of use to meet the needs of the most demanding user.
Medicine Products: